Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Neurocrine presented retrospective case series data for CRENESSITY in patients with 11β-hydroxylase deficiency, a rare CAH subtype not included in pivotal trials. The study of 15 patients showed median reductions of 92% in DOC and 95% in 11-deoxycortisol, with 14 of 15 patients able to reduce glucocorticoid doses.
Key figures
- Drug Name
- CRENESSITY (crinecerfont)
- Patient count
- 15
- Adult patients
- 4
- Pediatric patients
- 11
- Median a4 reduction
- -65%
- Median doc reduction
- -92%
- Median 11df reduction
- -95%
- Patients reducing gc dose
- 14/15
- Patients reducing antihypertensives
- 2/5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.